Biopharmaceutical company InflaRx has launched Gohibic (vilobelimab) in the US for the treatment of Covid-19. In April 2023, Gohibic was granted an Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) in hospitalised adults when initiated within 48 hours of receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). Professor Niels […]